Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.56 |
| ▸ | GRM4 | Q14833 | 6/20 | 0.56 |
| ▸ | FADS1 | O60427 | 7/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.46 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4514088 | 0.88 | GSK3B (0.56) | GSK3BGRM4FADS1TRPA1 | |
| SCHEMBL4507100 | 0.87 | FADS1 (0.72) | GSK3BGRM4FADS1TRPA1 | |
| SCHEMBL13789198 | 0.81 | GSK3B (0.59) | GSK3BGRM4FADS1TRPA1 | |
| SCHEMBL4738081 | 0.80 | FADS1 (0.64) | GRM4FADS1NTRK1TRPA1 | |
| SCHEMBL11701839 | 0.77 | GSK3B (0.66) | GSK3BFADS1NTRK1 | |
| SCHEMBL4782909 | 0.76 | FADS1 (0.80) | GSK3BGRM4FADS1TRPA1 | |
| SCHEMBL4007120 | 0.76 | GSK3B (0.69) | GSK3BGRM4FADS1NTRK1 | |
| SCHEMBL4743301 | 0.74 | FADS1 (0.72) | GSK3BGRM4FADS1TRPA1 | |
| SCHEMBL7571499 | 0.73 | GSK3B (0.51) | GSK3B | |
| SCHEMBL29644051 | 0.73 | GSK3B (0.51) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560467-B2 | Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-14 | — | — | US | claimed |
| EP-1633740-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-11-19 | — | — | EP | claimed |
| JP-2007516173-A | — | — | 2007-06-21 | — | — | JP | claimed |
| US-20070099944-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2007-05-03 | — | — | US | claimed |
| EP-1633740-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2006-03-15 | — | — | EP | claimed |
| WO-2004112719-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-29 | — | — | WO | claimed |
| US-7560467-B2 | Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| EP-1633740-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20070099944-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2007-05-03 | — | — | US | disclosed |
| EP-1633740-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004112719-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099944-A1 | Chemical compounds | ROCK1, ROCK2, CIT | GSK3B 104/4885GRM4 1791/4885FADS1 3211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.